Radiation Therapy for Prostate Cancer

Surgical Oncology Clinics of North America

Volumn 22, Issue 3, 2013, Pages 483-494

  Koontz, Bridget F ^a   Lee, W Robert ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; IMRT; Palliation; Postoperative; Radiotherapy

Indexed keywords

PLACEBO; RADIOPHARMACEUTICAL AGENT; RADIUM 223; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; BONE MARROW SUPPRESSION; BONE METASTASIS; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; REVIEW; SALVAGE THERAPY; TREATMENT DURATION; TREATMENT PLANNING;

BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84876866533     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.02.006     Document Type: Review

References (71)

1. American Cancer Society. Cancer facts and figures 2012. Available at: Accessed February 28, 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf.
2. Meltzer D., Egleston B., Abdalla I. Patterns of prostate cancer treatment by clinical stage and age. Am J Public Health 2001, 91(1):126-128.
3. Dinan M.A., Robinson T.J., Zagar T.M., et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys 2012, 82(5):e781-e786.
4. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 53(1):91-98.
5. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44(4):789-799.
6. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008, 179(Suppl 5):S20-S24.
7. Koontz B.F., Chino J., Lee W.R., et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy 2009, 8(2):191-196.
8. Lawton C.A., Hunt D., Lee W.R., et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 2011, 81(1):1-7.
9. Lawton C.A., Yan Y., Lee W.R., et al. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 2012, 82(5):e795-e801.
10. Keyes M., Miller S., Moravan V., et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2009, 73(4):1023-1032.
11. Keyes M., Spadinger I., Liu M., et al. Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients. Brachytherapy 2012, 11(3):199-208.
12. Theodorescu D., Gillenwater J.Y., Koutrouvelis P.G. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000, 89(10):2085-2091.
13. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358(12):1250-1261.
14. Viani G.A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74(5):1405-1418.
15. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23(25):6132-6138.
16. Yeoh E.E., Fraser R.J., McGowan R.E., et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. Int J Radiat Oncol Biol Phys 2003, 55(4):943-955.
17. Arcangeli G., Fowler J., Gomellini S., et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1013-1021.
18. Pollack A., Walker G., Buyyounouski M.K., et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81(2):S1.
19. Kuban D.A., Nogueras-Gonzalez G.M., Hamblin L., et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofraction. Int J Radiat Oncol Biol Phys 2010, 78(3):S58-S59.
20. Freeman D.E., King C.R. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3.
21. Boike T.P., Lotan Y., Cho L.C., et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011, 29(15):2020-2026.
22. Sheets N.C., Goldin G.H., Meyer A.M., et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012, 307(15):1611-1620.
23. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1124-1129.
24. Bortfeld T. IMRT: a review and preview. Phys Med Biol 2006, 51(13):R363-R379.
25. Webb S. The physical basis of IMRT and inverse planning. Br J Radiol 2003, 76(910):678-689.
26. Middleton M., Frantzis J., Healy B., et al. Successful implementation of image-guided radiation therapy quality assurance in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. Int J Radiat Oncol Biol Phys 2011, 81:1576-1581.
27. Trichter F., Ennis R.D. Prostate localization using transabdominal ultrasound imaging. Int J Radiat Oncol Biol Phys 2003, 56(5):1225-1233.
28. Quigley M.M., Mate T.P., Sylvester J.E. Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses. Urol Oncol 2009, 27(5):473-482.
29. Barney B.M., Lee R.J., Handrahan D., et al. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT). Int J Radiat Oncol Biol Phys 2011, 80:301-305.
30. van Zijtveld M., Dirkx M., Breuers M., et al. Evaluation of the 'dose of the day' for IMRT prostate cancer patients derived from portal dose measurements and cone-beam CT. Radiother Oncol 2010, 96(2):172-177.
31. Ezzell G.A., Burmeister J.W., Dogan N., et al. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys 2009, 36(11):5359-5373.
32. Ezzell G.A., Galvin J.M., Low D., et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. Med Phys 2003, 30(8):2089-2115.
33. Klein E.E., Hanley J., Bayouth J., et al. Task Group 142 report: quality assurance of medical accelerators. Med Phys 2009, 36(9):4197-4212.
34. Trofimov A., Nguyen P.L., Coen J.J., et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 2007, 69(2):444-453.
35. Alicikus Z.A., Yamada Y., Zhang Z., et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011, 117:1429-1437.
36. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71(4):1028-1033.
37. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28(7):1106-1111.
38. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11(11):1066-1073.
39. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26(4):585-591.
40. Jones C.U., Hunt D., McGowan D.G., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365(2):107-118.
41. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360(24):2516-2527.
42. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25(17):2420-2425.
43. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24(27):4448-4456.
44. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009, 27(1):92-99.
45. Takeda K., Takai Y., Narazaki K., et al. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intraprostate fiducial markers for localized prostate cancer at a single institute in Japan. Radiat Oncol 2012, 7(1):105.
46. Morgan P.B., Ruth K., Horwitz E.M., et al. A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: toxicity and outcomes. Int J Radiat Oncol Biol Phys 2007, 69(3):S319.
47. Alemozaffar M., Regan M.M., Cooperberg M.R., et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011, 306(11):1205-1214.
48. Mantz C.A., Nautiyal J., Awan A., et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am 1999, 5(4):230-236.
49. Burri R.J., Stone N.N., Unger P., et al. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77(5):1338-1344.
50. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53(1):2-10.
51. Anscher M.S., Prosnitz L.R. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1987, 138(6):1407-1412.
52. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25(15):2035-2041.
53. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008, 299(23):2760-2769.
54. Bolla M., Van Poppel H., Tombal B., et al. 10-year results of adjuvant radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911). Int J Radiat Oncol Biol Phys 2010, 78(3):S29.
55. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181(3):956-962.
56. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27(18):2924-2930.
57. Van der Kwast T.H., Bolla M., Van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25(27):4178-4186.
58. van der Linden Y.M., Lok J.J., Steenland E., et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004, 59(2):528-537.
59. Hartsell W.F., Scott C.B., Bruner D.W., et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005, 97(11):798-804.
60. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999, 52(2):111-121.
61. Gogna N.K., Baxi S., Hickey B., et al. Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer. Int J Radiat Oncol Biol Phys 2012, 83(2):e205-e211.
62. Spanos W.J., Clery M., Perez C.A., et al. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys 1994, 29(5):961-967.
63. Porter A.T., McEwan A.J., Powe J.E., et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993, 25(5):805-813.
64. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63(5):940-945.
65. Parker C., Heinrich D., O'Sullivan J.M., et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012, 30(5S). abstract 8.
66. Wallace K., Fleshner N., Jewett M., et al. Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2006, 24(25):4158-4162.
67. Vicini F.A., Martinez A., Hanks G., et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002, 95(10):2126-2135.
68. Grimm P., Billiet I., Bostwick D., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012, 109(Suppl 1):22-29.
69. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299(3):289-295.
70. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61(5):1285-1290.
71. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26(15):2497-2504.